Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07410507 · ClinicalTrials.gov registry record · Phase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
A Phase 2 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 450
- Enrollment target
NCT07410507: Recruiting Phase 2 study, sponsored by Eli Lilly and Company.
NCT07410507 is a Phase 2 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 450 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (238% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07410507, a Phase 2 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 450 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment period will last a maximum of 12 months, and the follow up period will last approximately 2 months. The length of time of your study participation may last up to approximately 15 months.
Interventions
- DRUG Placebo
- DRUG Brenipatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT07410507 shows while recruiting
NCT07410507 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (238% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07410507 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07410507 about?
NCT07410507 is a clinical study titled "A Study of Brenipatide in Adult Participants With Schizophrenia". The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe...
What is the current status of trial NCT07410507?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 450 participants. The study started on 2026-02-10. Estimated completion is 2027-11.
What interventions are being tested in trial NCT07410507?
The interventions under investigation include: Placebo (DRUG), Brenipatide (DRUG).
Who is sponsoring clinical trial NCT07410507?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07410507's enrollment target sits among peer trials
450 87th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI